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Background to the debate: The human rights responsi-
bilities of drug companies have been considered for years
by nongovernmental organizations, but were most
sharply defined in a report by the UN Special Rapporteur
on the right to health, submitted to the United Nations
General Assembly in August 2008. The ‘‘Human Rights
Guidelines for Pharmaceutical Companies in relation to
Access to Medicines’’ include responsibilities for transpar-
ency, management, monitoring and accountability, pric-
ing, and ethical marketing, and against lobbying for more
protection in intellectual property laws, applying for
patents for trivial modifications of existing medicines,
inappropriate drug promotion, and excessive pricing. Two
years after the release of the Guidelines, the PLoS Medicine
Debate asks whether drug companies are living up to
their human rights responsibilities. Sofia Gruskin and Zyde
Raad from the Harvard School of Public Health say more
assessment is needed of such responsibilities; Geralyn
Ritter, Vice President of Global Public Policy and
Corporate Responsibility at Merck & Co. argues that
multiple stakeholders could do more to help States
deliver the right to health; and Paul Hunt and Rajat
Khosla introduce Mr. Hunt’s work as the UN Special
Rapporteur on the right to the highest attainable standard
of health, regarding the human rights responsibilities of
pharmaceutical companies and access to medicines.
This is the second of three viewpoints examining the question of whether
pharmaceutical companies are living up to their human rights
responsibilities.
As a global health care company, Merck believes that helping to
address global health challenges is a strategic and humanitarian
imperative. While States bear primary responsibility for the
realization of the right to health, it requires a genuine effort
among many actors, including governments, multilateral organi-
zations, nongovernmental organizations, health care professionals,
and the pharmaceutical industry. This collaboration is particularly
important given the many complex factors that adversely affect the
right to health, such as poverty, poor infrastructure and
distribution channels, corruption, lack of health care education
and awareness, inadequate public health services, and lack of
adequately trained health care professionals.
The Role of the Pharmaceutical Industry in
Relation to the Right to Health
The pharmaceutical industry can and should leverage its
expertise to help States achieve the full realization of the right to
health and should work in partnership with them and other actors
to help remove barriers that stand between patients and the health
care they need. It is the right thing to do not only from a moral
perspective, but from a long-term commercial perspective as well.
The primary role of the pharmaceutical industry in realizing the
right to health is through its core capabilities of researching,
developing, and producing medicines and vaccines to address
unmet medical needs, and in helping to ensure their appropriate
distribution. In this role over the past century, the industry has
helped to save or improve the quality of millions of lives. For
example, the industry’s role in developing and distributing vaccines
for diseases such as measles has supported the near elimination of
that disease in many regions of the world [1]. Pharmaceutical
companies have also created and delivered antiretrovirals that have
saved millions of lives in the global fight against HIV/AIDS [2].
In fulfilling this primary role, the industry must of course act in a
responsible manner – protecting employee safety, working to
reduce its environmental impact in local communities, and
safeguarding the safety and privacy of clinical trial participants.
Membership of many companies in the UN Global Compact
reflects this commitment to responsible behavior.
The role of the pharmaceutical industry in promoting access to
medicines has received particular attention. In recent years,
pharmaceutical companies have strengthened their focus on ways
they can support and promote access to health, especially in
developing countries, where the needs and challenges are so
significant. Areas where the pharmaceutical industry can play an
important role, working with States and other partners, include
the following:
N Discovering and developing new medicines for ne-
glected diseases prevalent in developing countries. In
2008, 67 company-backed projects targeting the ten priority
‘‘neglected’’ diseases were ongoing. The G-FINDER survey of
neglected diseases R&D found that the biopharmaceutical
industry was the third largest provider of R&D funding in
2008, after the U.S. government and the Bill & Melinda Gates
Foundation [3]. Much of the research is done through
partnerships. For example, in 2009 Merck entered into an
agreement with DNDi (Drugs for Neglected Diseases initiative;
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N Developing new approaches to help foster access to
medicines in emerging and least developed countries.
In the past decade, many pharmaceutical companies have
implemented innovative differential pricing frameworks that
reflect levels of economic development, payer category, and
disease burden. Merck was one of the first in the industry to
have a formal policy of differential pricing for its antiretroviral
medicines and newest vaccines (http://www.merck.com/
corporate-responsibility/access/access-developing-emerging/
approach.html), and has since taken the approach of
differentiating its pricing based upon a particular country’s
level of economic development for many of its newer products
for chronic disease, such as its medicine for type 2 diabetes.
Another tool to improve access is voluntary licensing. Many
companies have granted voluntary licenses to generic compa-
nies to improve access to medicines in resource-limited
countries. The industry has also developed philanthropic
partnerships to help foster access, such as the MECTIZAN
Donation Program (http://www.mectizan.org/history),
through which Merck works with the World Health Organi-
zation, the World Bank, ministries of health, nongovernmental
organizations, and local communities to provide medicine free
of charge to more than 80 million people annually to treat
river blindness.
N Supporting efforts beyond drug development and
delivery, including helping States build health care
capacity and strengthen health systems. Grave systemic
obstacles in many countries hinder progress toward achieve-
ment of the right to health. Although clearly a State
responsibility to address, many pharmaceutical companies
have undertaken a variety of programs and partnerships to
support State efforts to strengthen national health care systems.
Merck has worked, for example, with the government of
Botswana (http://www.merck.com/corporate-responsibility/
access/access-hiv-aids/access-hiv-aids-ACHAP-botswana/
home.html) and the Bill & Melinda Gates Foundation for the
past ten years to develop and implement a comprehensive
approach to the HIV/AIDS pandemic that addresses
treatment, prevention, care, and support. Botswana’s PMTCT
and treatment programs have resulted in halving the mortality
rate in adults in that country between 1980 and 2007 [4].
PEPFAR also reports a dramatic reduction of mother-to-child
transmission in Botswana, leading to an 80% reduction in new
infections among children (http://www.pepfar.gov/press/
79674.htm). Such programs are not unique to Merck; a recent
study by the International Federation of Pharmaceutical
Manufacturers & Associations reported that there are 213
industry partnership programs to help improve health in
developing countries [5].
What More Should Be Done to Realize the Right to
Health?
While States must continue to bear primary responsibility for
the realization of the right to health, its attainment requires a
multi-stakeholder approach. Everyone has a role to play and
everyone can do more.
Pharmaceutical companies could better assess their role and
monitor their contributions to advancing the achievement of the
right to health. To this end, more companies could document their
contributions to the health-related UN Millennium Development
Goals. Several companies are working with the Danish Institute
for Human Rights to develop a sector-specific human rights
assessment tool that will examine core activities—including
research and development, registration, pricing, licensing, and
donations—that are fundamental to improving access both to
medicines and health care overall. Such efforts should continue.
Increasing transparency is another area where notable progress
has been made by the industry but opportunities for improvement
still exist.
Progress is possible, but it will require the international
community coming together to support States’ obligations and
committing to meaningful dialogue on the true barriers and
drivers for realizing the right to health.
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